Cortexyme Company

Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.


Investors

Industry: Biotechnology, Health Care, Medical, Pharmaceutical
Investment Stage: N/A
Last Funding Date: 2019
Investors Number: 13
Technology: Gene therapy
Last Funding Type: Post-IPO Equity
Headquarters: South San Francisco, California, United States
Founded Date: 2012
Investor Type: N/A
Funding Status: IPO
Total Funding: 225000000
Estimated Revenue: $10M to $50M
Number Of Exists: N/A
Employee Number: 11-50